NEW YORK (GenomeWeb) – MDNA Life Sciences announced today an exclusive licensing agreement with Laboratory Corporation of America for a liquid biopsy-based noninvasive test for patients who may have prostate cancer.
Under the terms of the deal, which covers the US, LabCorp will be able to use MDNA’s technology to develop and commercialize a test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
Financial and other terms of the agreement were not disclosed.
Based in West Palm Beach, Florida, MDNA is a molecular diagnostics company using liquid biopsy technology based on the mitochondrial genome. In late 2016 it launched its first noninvasive blood-based cancer test for prostate cancer test, signaling its move into the liquid biopsy space.
“We believe that the future commercialization of this unique biomarker will have a significant impact on how prostate biopsy decisions are made going forward, and we are very excited to be working with LabCorp to increase patient access to this technology in the U.S. market,” MDNA CEO Chris Mitton said in a statement.